key: cord-0738430-9p1kscue
authors: Anderson, David A.; Godfrey, Dale I.
title: Letter to the editor RE: Lake et al., 2022 comment on Fulford et al., 2021 ‘A point-of-care lateral flow assay for neutralizing antibodies against SARS-CoV-2’
date: 2022-03-09
journal: EBioMedicine
DOI: 10.1016/j.ebiom.2022.103899
sha: 0a46d66f2774e1b0c8dd21b76eb7cba89b7ae4b8
doc_id: 738430
cord_uid: 9p1kscue

nan

In our recent eBioMedicine publication 1 we included the statement in "Evidence before this study" that PubMed literature searches, including MedRxiv pre-print servers as well as manual searches in relevant papers up to 11 October 2021, did not reveal prior reports of "deployable, visual point of care test for measuring levels of protective levels of SARS-CoV-2 protection".

Lake et al. have asserted that this statement was incorrect because of their lateral flow test as described in a MedRxiv pre-print posted in December 2020 2 (reference 18 in our publication). We believe that our statement of "Evidence before this study" was factually correct with regard to the December 2020 pre-print by Lake et al 2 and a second version posted in March 2021, which did not include evidence for detection of neutralising antibodies in authentic whole blood samples, instead using contrived whole blood samples prepared via the addition of neutralising monoclonal antibodies.

However, we acknowledge and regret that we had overlooked the posting of a third version pre-print on 25 May 2021 3 which did include the relevant data using authentic whole blood samples, which we consider as a key criteria for a "deployable" test. A similar oversight appears to have occurred in the recent publication from Lake et al., 4 as we note that these authors did not cite our own pre-print of our lateral flow assay that was published on MedRXiv on 12th April 2021, 5 and updated on MedRXiv in June 2021.

We agree with Lake and colleagues, that point of care tests for neutralising antibodies as described by Lake et al and our own test are likely to be important tools in managing the ongoing SARS-CoV-2 pandemic, especially with regard to emerging variants of concern such as Omicron.

DA and DG wrote and edited this article.

DAA and DIG report a patent Australian Provisional Patent Application 2021901011 (filed 7 April 2021) "Point of care lateral flow test for COVID19 detection" and grants from the Government of the State of Victoria, during the conduct of the study.

A point-of-care lateral flow assay for neutralising antibodies against SARS-CoV-2

Development of a rapid point-of-care test that measures neutralizing antibodies to SARS-CoV-2

Development of a rapid point-of-care test that measures neutralizing antibodies to SARS-CoV-2

Development of a rapid point-of-care test that measures neutralizing antibodies to SARS-CoV-2

A point-of-care lateral flow assay for neutralising antibodies against SARS-CoV-2. medRxiv